Related Experiment Video
Updated: Feb 18, 2026
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Antiviral Activity of Itraconazole against Echovirus 30 Infection In Vitro
Jae-Sug Lee1, Hwa-Jung Choi1, Jae-Hyoung Song2
1Department of Beauty Science, Kwangju Women's University, Gwangju, Korea.
Objectives:
Echovirus 30 is a major cause of meningitis in children and adults. The aim of this study was to investigate whether the antifungal drug itraconazole could exhibit antiviral activity against echovirus 30.
Methods:
The cytopathic effect and viral RNA levels were assessed in RD cells as indicators of viral replication. The effects of itraconazole were compared to those of two known antiviral drugs, rupintrivir and pleconaril. The time course and time-of-addition assays were used to approximate the time at which itraconazole exerts its activity in the viral cycle.
Results:
Itraconazole and rupintrivir demonstrated the greatest potency against echovirus 30, demonstrating concentration-dependent activity, whereas pleconaril showed no antiviral activity. Itraconazole did not directly inactivate echovirus 30 particles or impede viral uptake into RD cells, but did affect the initial stages of echovirus 30 infection through interference with viral replication.
Conclusion:
Itraconazole can be considered a lead candidate for the development of antiviral drugs against echovirus 30 that may be used during the early stages of echovirus 30 replication.
Insights
The antifungal drug itraconazole shows promise as an antiviral treatment for echovirus 30 infections. It effectively inhibits viral replication in early infection stages, making it a potential candidate for new echovirus 30 therapies.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- Echovirus 30 is a significant pathogen causing meningitis in both pediatric and adult populations.
- Current therapeutic options for echovirus 30 infections are limited, necessitating the exploration of novel antiviral agents.
Purpose of the Study:
- To evaluate the potential antiviral activity of the antifungal drug itraconazole against echovirus 30.
- To compare the efficacy of itraconazole with established antiviral compounds like rupintrivir and pleconaril.
Main Methods:
- Viral replication was assessed by monitoring cytopathic effects and viral RNA levels in infected RD cells.
- Itraconazole's antiviral effects were determined through time-course and time-of-addition assays to pinpoint its mechanism of action.
- Comparative analysis with rupintrivir and pleconaril was conducted to establish relative potency.
Main Results:
- Itraconazole exhibited significant, concentration-dependent antiviral activity against echovirus 30, similar to rupintrivir.
- Pleconaril demonstrated no significant antiviral effect on echovirus 30.
- Itraconazole's mechanism involves interfering with early viral replication stages, not direct viral inactivation or cell entry inhibition.
Conclusions:
- Itraconazole emerges as a promising lead compound for developing new antiviral drugs targeting echovirus 30.
- Its efficacy in inhibiting early viral replication suggests potential for therapeutic intervention during the initial phases of infection.
